Based on sensitivities found in our drug screen, we selected 6 compounds which were not previously used for the treatment of liposarcoma: the proteasome inhibitor MLN2238, the PI3K/mTOR inhibitor GSK2126458, the histone deacetylase inhibitor JNJ-26481585, the multi-target drug triptolide, the survivin inhibitor YM155, and the NAMPT inhibitor APO866. Here, BIRC5 is linked to liposarcoma.